^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMCnyeso

    i
    Other names: IMCnyeso, GSK01, GSK3537142, NY-ESO-1 ImmTAC , 3537142, bispecific NY-ESO-1- and LAGE-1A-specific TCR/anti-CD3, HLA- A*0201-restricted NY-ESO-1- and LAGE-1A-specific soluble TCR/anti-CD3 bispecific molecule, NY-ESO-1, GSK1, GSK-01–NY-ESO
    Associations

    News

    Trials
    Company:
    GSK, Immunocore
    Drug class:
    Immunomodulator
    Related drugs:
    Associations

    News

    Trials
    11ms
    Modulation of TRPV4-mediated TNF-α expression in Müller glia and subsequent RGC apoptosis by statins. (PubMed, Exp Eye Res)
    Cells were pretreated with simvastatin or lovastatin before GSK101...Herein, we showed that statins can modulate gliosis and TNF-α expression in Müller cells, protecting RGCs. These data further support the neuroprotective effect of statins, promoting them as a potential treatment for glaucoma.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4)
    |
    IMCnyeso • lovastatin
    over2years
    Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)
    P1/2, N=29, Terminated, Immunocore Ltd | N=63 --> 29
    Enrollment change
    |
    CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01
    |
    IMCnyeso
    over3years
    Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)
    P1/2, N=63, Terminated, Immunocore Ltd | Active, not recruiting --> Terminated; Strategic decision to stop development and not based on any safety concerns
    Clinical • Trial termination
    |
    CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    HLA-A*02:01
    |
    IMCnyeso
    over3years
    Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CTAG1B (Cancer/testis antigen 1B) • CTAG2 (Cancer/testis antigen 2)
    |
    IMCnyeso